In gallbladder carcinoma, antisense-Bcl-2-siRNA against aberrantly expressed Bcl-2 gene (positive expression rate is ~23.4–51.7%) exerted significant tumor regression effect in a mouse model study [68,69,70,71]. This evidence concerns the gene BCL2 and neoplasm.